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Abstract
Purpose Mutations in the isocitrate dehydrogenase-1 gene (IDH1) occur at high frequency in grade II–III gliomas (LGGs). 
IDH1 mutations are somatic, missense and heterozygous affecting codon 132 in the catalytic pocket of the enzyme. In LGG, 
most mutations (90%) result in an arginine to histidine substitution  (IDH1R132H) providing a neo-epitope that is expressed 
in all tumor cells. To assess the immunogenic nature of this epitope, and its potential use to develop T cell treatments, we 
measured  IDH1R132H-specific B and T cell reactivity in blood and tumor tissue of LGG patients.
Methods Sera from  IDH1R132H-mutated LGG patients (n = 27) were assayed for the presence of a neo-specific antibody 
response using ELISA. In addition, PBMCs (n = 36) and tumor-infiltrating lymphocytes (TILs, n = 10) were measured for 
T cell activation markers and IFN-γ production by flow cytometry and ELISA. In some assays, frequencies of CD4 T cells 
specific for mutated peptide presented by HLA-DR were enriched prior to T cell monitoring assays.
Results Despite high sensitivity of our assay, we failed to detect  IDH1R132H-specific IgG in sera of LGG patients. Similarly, 
we did not observe CD4 T cell reactivity towards  IDH1R132H in blood, neither did we observe such reactivity following pre-
enrichment of frequencies of  IDH1R132H-specific CD4 T cells. Finally, we did not detect  IDH1R132H-specific CD4 T cells 
among TILs.
Conclusions The absence of both humoral and cellular responses in blood and tumors of LGG patients indicates that 
 IDH1R132H is not sufficiently immunogenic and devaluates its further therapeutic exploitation, at least in the majority of 
LGG patients.
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Introduction
Gliomas are the most common primary brain cancers in 
adults. The WHO currently classifies these tumors based 
on histological and genetic features into oligodendroglioma, 
astrocytoma and glioblastoma [1]. Approximately 80% of 
grade II and III tumors harbor driver mutations in isoci-
trate dehydrogenase (IDH) 1 or 2 genes and are classified 
as diffuse low-grade gliomas (LGG). Grade IV glioma are 
classified as high-grade glioma (HGG) and can be distin-
guished in either primary (IDH wildtype) or secondary (IDH 
mutant) gliomas [2, 3]. A subset of LGG will progress to 
HGG within months, while others remain stable for years 
[4]. Despite advances in neurosurgery, radiotherapy and 
chemotherapy, almost all glioma patients ultimately die of 
the disease and thus novel treatment modalities need to be 
urgently developed.
Recent clinical studies have indicated vaccine- and T cell-
based immune therapies as potentially effective novel treat-
ment options for different cancer types [5–8]. For instance, 
adoptive T cell therapies (ACTs) targeting CD19 have shown 
durable remissions in patients with refractory B cell ALL 
and large B cell lymphoma respectively, which has led to 
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FDA approvals of these T cell products to treat B cell malig-
nancies [9, 10]. However, reactivity of therapeutic T cells 
against healthy tissues has resulted in severe toxicities in 
recent trials for cancer patients [11–13]. This stressed the 
importance to select tumor antigens as well as their cor-
responding chimeric antigen receptors (CARs) or T cell 
receptors (TCRs) to minimize chances of on- or off-target 
toxicities [6, 14, 15].
Neoantigens constitute a class of tumor antigens that 
appear to represent ideal targets for adoptive T cell therapy. 
These antigens arise from tumor-specific mutations that 
alter amino acid coding sequences, and hence are not pre-
sent in any healthy tissues. Different studies have already 
focused on the therapeutic targeting of neoantigens derived 
from hallmark glioma mutations, for instance the epidermal 
growth factor receptor (EGFRvIII), histone H3 (H3.3K27M) 
and isocitrate dehydrogenase 1  (IDH1R132H) [16–20]. The 
 IDH1R132H mutation accounts for the vast majority (~ 90%) 
of all mutations in IDH1 and results in an arginine to histi-
dine amino acid substitution at codon 132 of this gene [21]. 
Besides a clear role of this mutant in gliomagenesis through 
the production of the oncometabolite d-2-hydroxyglutarate 
[22], the  IDH1R132H mutation may provide a unique target 
for immune therapies as its expression is very frequent, sta-
ble and present in all tumor cells [23, 24]. In fact, it has 
previously been established that  IDH1R132H can be presented 
by HLA-DR, and a spontaneous humoral as well as CD4 
T cell response may occur in a subset of glioma patients 
[20, 25]. In order to develop effective immune therapies tar-
geting  IDH1R132H, it is critical to assess the frequency and 
extent of  IDH1R132H-specific immune reactivity in a cohort 
of LGG patients. In the current study, we therefore set out 
to determine the presence of humoral and cellular immune 
responses directed against  IDH1R132H, both in peripheral 
blood and tumor tissue of LGG patients.
Materials and methods
Patients and patient samples
Patients with  IDH1R132H-mutated grade II and III glioma 
were diagnosed at Erasmus University Medical Center 
(Rotterdam, The Netherlands). PBMCs and sera were pro-
spectively collected from glioma patients (prior to surgery) 
and from healthy donors. Formalin-fixed, paraffin-embed-
ded (FFPE) tumor tissue samples were routinely collected 
for diagnostic purposes. For experiments using TILs, we 
obtained fresh tissue directly from the operating theatre 
from suspected LGG patients. The IDH1 mutation status 
of these tissues was determined following resection by next 
generation targeted resequencing or immunohistochem-
istry [23, 26]. In case of unknown IDH1 mutation status, 
we performed sanger sequencing on DNA isolated from 
FFPE tumor tissue samples as described previously [27]. 
All patients provided written informed consent according 
to national and local regulations for correlative tissue stud-
ies. The study was approved by the institutional ethics com-
mittee. Patient characteristics are listed in Supplementary 
table 1.
HLA‑DRB1 typing
HLA-DRB1 typing (low resolution, 2 digit) was performed 
by Sanquin Diagnostic Services (Amsterdam, the Nether-
lands) using PCR-SSP on DNA isolated from patient PBMC 
[28].
Peptides
Supplementary table 2 shows an overview of used human 
 IDH1WT and  IDH1R132H peptides, which were reported to 
trigger IgG and CD4 T cell reactivity [20]. Negative control 
peptide used for T cell stimulation assays was human mye-
lin oligodendrocyte glycoprotein. Staphylococcus-derived 
enterotoxin B (SEB) was used as positive control (Sigma-
Aldrich, Zwijndrecht, the Netherlands). Peptides were syn-
thesized by Pepscan (Lelystad, the Netherlands).
Anti‑IDH1R132H IgG ELISA
Pierce Streptavidin Coated High Sensitivity Plates (Ther-
moFisher, Landsmeer, the Netherlands) were washed in a 
HydroFlex microplate washer (Tecan, Giessen, the Nether-
lands) using PBS/0.05% Tween20 (Sigma-Aldrich). Plates 
were coated with 3 µM peptide in PBS/0.05% Tween20 for 
1 h. Plates were washed and PBS/0.05% Tween20 + 10% 
FBS was added to each well (1 h) in order to reduce non-
specific antibody binding. Sera from  IDH1R132H-mutant 
glioma patients (1:100) were added for 1 h. Plates were 
washed again and secondary goat anti-human-HRP antibody 
(1:1000, PI-3000, Vector, Brunschwig chemie, Amsterdam, 
the Netherlands) was added for 1 h. Primary mouse anti-
human  IDH1R132H antibody [Clone: H09, 1:5000, Dianova 
(Bio-Connect, Huissen, the Netherlands)] was used as posi-
tive control, to which end, rabbit anti-mouse-HRP antibody 
(1:1000, P0260, DAKO (Agilent Technologies, Amstelveen, 
the Netherlands)) was added as second step. After a final 
wash step, 3,3′,5,5′-tetramethylbenzidine (Sigma-Aldrich) 
was added and incubated until color developed. Reaction 
was stopped by addition of 1 M hydrochloric acid, and opti-
cal densities (OD) at 450 nm were measured using a Multi-
skan Ascent Plate Reader (ThermoFisher). All experiments 
were performed at room temperature.
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PBMCs: isolation, enrichment for peptide‑specificity 
and peptide stimulation
PBMC were isolated from heparin blood by density-gradient 
centrifugation using Ficoll-Paque PLUS (Sigma-Aldrich). 
Viable cells and leukocytes were stained using Tuerk solu-
tion (Sigma-Aldrich) and Tryptan Blue (ThermoFisher), 
and microscopically counted. Patient PBMC (2 × 106 cells) 
were stimulated with 17.5 µM  IDH1R132H,  IDH1wt, MOG, 
or 1 µg/mL staphylococcus-derived enterotoxin B (SEB, 
Sigma-Aldrich) in 400 µL Iscove’s Modified Dulbecco’s 
Medium (IMDM) containing 2% l-glutamine, 1% penicillin 
and streptomycin, supplemented with 6% allogeneic human 
serum at 37 °C for 16 h.
In some experiments, effector T cells were co-cultured 
together with peptide-loaded antigen presenting cells 
prior to peptide stimulation. HeLa cells stably expressing 
DRA1*01:01 and DRB1*01:01 (DR1 + HeLa) or stably 
expressing DRA1*01:01 and DRB1*04:01 (DR4 + HeLa) 
(kind gift from prof. Fred Falkenburg, LUMC, The Nether-
lands) [29] were irradiated and added to 96 well tissue cul-
ture treated plates (Sigma-Aldrich, 0.05 × 105/well) together 
with autologous patient PBMC (0.4 × 105/well) and 17.5 µM 
or no peptide in IMDM supplemented with 10 ng/mL IL-7 
(200 µL/well). Cells were co-cultured for 3–4 weeks and 
additional cytokines were added. Day 0: 10 ng/mL IL-7, 
day 3: 22 ng/mL IL-15, day 6: 100 IU/mL IL-2, day 13: 
10 ng/mL IL-7, 1 ng/mL IL-15 and 100 IU/mL IL-2. Cells 
were split using IMDM containing 360 IU/mL IL-2. Follow-
ing co-culture, T cells were harvested, washed and assayed 
(0.2 × 106) for their reactivity upon stimulation with pep-
tide-loaded DR1+, DR4+ or non-transduced HeLa cells 
(0.2 × 106) at 37 °C for 16 h.
TILs: isolation and peptide stimulation
TIL microcultures were initiated and expanded from 
tumor fragments as described previously [30]. In short, 
suspected LGG tissue was freshly obtained, washed with 
PBS and cut in small pieces. Single tumor fragments were 
placed in each well of a 24-well tissue culture plate with 
2 mL of Roswell Park Memorial Institute (RPMI) 1640 
medium containing 2% l-glutamine, 25  mM HEPES, 
1% penicillin and streptomycin, supplemented with 6% 
allogeneic human serum and 1000  IU/mL IL-2 (TIL 
medium) at 37 °C. After 2 weeks of culture, contents 
of wells with clearly visible lymphocyte growth were 
pooled for each LGG. Viable cells and leukocytes were 
stained using Tuerk solution (Sigma-Aldrich) and Tryptan 
Blue (ThermoFisher), and subsequently microscopically 
counted. Successful cultures of TILs were verified with 
CD3 flow cytometry (see “Methods” below). To assay 
reactivity, TILs (2 × 106) were plated with 0.5 × 106 target 
cells (irradiated autologous PBMC pulsed with 17.5 µM 
 IDH1R132H,  IDH1wt, no peptide) or 1  µg/mL SEB in 
200 µL IMDM containing 2% l-glutamine, 1% penicil-
lin and streptomycin, supplemented with 6% allogeneic 
human serum at 37 °C for 16 h.
T cell CD137 expression and IFN‑γ production
Following T cell stimulations, 2.5 µL PerCP-conjugated 
mouse anti-human CD45 (BD Biosciences, Vianen, the 
Netherlands), 5 µL FITC-conjugated mouse anti-human 
CD3 (BD Biosciences), 5 µL PE-conjugated mouse anti-
human CD4 (Beckman Coulter, Woerden, the Netherlands) 
and 5 µL APC-conjugated mouse anti-human CD137 (BD 
Biosciences) were premixed in 50 µL PBS and added to cell 
pellets. Samples were incubated at 4 °C for 30 min, fixed 
with paraformaldehyde 1% and measured on a FACS Canto 
(BD Biosciences). Lymphocyte populations were gated 
using forward scatter (FSC) and side scatter (SSC) plots, 
and within these lymphocytes CD45+ cells and CD4+ T 
cells were sequentially gated, after which the latter cells 
were assessed for CD137 surface expression (Supplementary 
Fig. 1). Flow cytometric analysis was performed using FCS 
Express 4 Flow software. Supernatants of T cells following 
stimulation with peptides or controls were analyzed for the 
presence of IFN-γ using Human IFN-γ ELISA Ready-SET-
Go! kit (ThermoFisher) according to the manufacturer’s 
instructions.
Statistics
Statistical analysis was performed using RStudio software 
and statistical methods used are specified in the figure 
legends.
Results
No detection of IDH1R132H‑specific antibodies 
in patient serum
We first aimed to identify humoral responses targeting the 
R132H neo-epitope. To this end, we have performed ELISA 
measurements to detect  IDH1R132H-specific IgG using 
sera from LGG patients who harbored the IDH1 mutation 
(n = 27). Healthy donor sera were included as negative con-
trols (n = 5). Using the experimental setup as depicted in 
Fig. 1a, we observed that sera of most patients provided 
ELISA signals comparable to those of negative controls. 
However, in 3 out of 27 samples (patients 6, 15 and 19), we 
observed an increased antibody signal towards  IDH1R132H 
peptide (Fig. 1b). Given the fact that both  IDH1R132H and 
scrambled peptides revealed equal signals for these patients 
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(Fig. 1c), these signals were interpreted as non-specific. 
These findings argue that no  IDH1R132H-specific antibodies 
are present in serum of 27  IDH1R132H-mutant LGG patients.
No detection of  IDH1R132H‑specific T cells in patient 
blood
Next, we screened  IDH1R132H-mutant glioma patients’ blood 
for T cell reactivity against this mutant peptide. For this, 
PBMCs, that contain a mixture of antigen presenting cells 
and effector T cells, were derived from 30 LGG patients and 
Fig. 1  Sera of LGG patients do 
not contain  IDH1R132H-specific 
IgG antibodies. a ELISA-
based detection scheme of 
 IDH1R132H-specific IgG 
antibodies. b Serum samples 
from  IDH1R132H-positive LGG 
patients were screened for 
mutation-specific IgG anti-
bodies. In 24 out of 27 sera, 
 IDH1R132H peptide-coated wells 
showed (background) signals 
comparable to those of healthy 
controls. Dashed line indi-
cates cut-off for positivity for 
 IDH1R132H-specific IgG defined 
as the mean of healthy control 
values + 3 × SD. c  IDH1R132H 
peptide and scrambled peptide-
coated wells were incubated 
with sera from patients that 
showed increased optical densi-
ties (patients 6 and 19; only 
samples were re-tested when 
sufficient sera were available). 
Same experimental setup was 
used as in (a). Mutant peptide 
wells did not show increased 
absorbance when compared to 
scrambled peptide wells. Assay 
was performed in triplicate for 
all 27 patient sera. Data are 
represented as mean ± SEM. 
αIDH1R132H: primary anti-
IDH1R132H antibody, positive 
control
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loaded with  IDH1R132H peptide or control peptides, and after 
a short-term stimulation, T cells were assessed for up-regu-
lated surface expression of CD137 and production of IFN-
γ, both measures of TCR-mediated activation. As the used 
 IDH1R132H peptide has been reported to be promiscuous with 
respect to MHC class II, particularly HLA-DR alleles, no 
pre-selection of LGG patients was performed based on HLA 
alleles [20]. None of 30 patient PBMC samples stimulated 
with  IDH1R132H peptide showed an increased frequency of 
CD4 T cells expressing CD137 compared to non-mutated 
peptide (Fig. 2a). Supplementary Fig. 1 shows the gating 
strategy used in this experiment. No increased frequency of 
CD137-positive CD8 T cells was observed in mutant peptide 
stimulation conditions either (data not shown). With respect 
to IFN-γ, measured in supernatants from the same samples, 
again no enhanced responses were observed in IDH1 mutant 
versus wildtype peptide stimulations (Fig. 2b).
Frequencies of peripheral T cells directed against tumor 
antigens are generally very low in patients [31, 32]. For 
instance, frequencies of neoantigen-specific T cells in mela-
noma have been reported to range from 0.002% to at most 
0.4% of PBMCs [33]. To address this challenge, we set up 
a co-culture system to enrich the frequency of  IDH1R132H 
peptide-specific T cells prior to analyzing peptide reactivity. 
We have previously shown the feasibility of pre-enrichment 
of antigen-reactive T cells without loss of T cell specific-
ity [29, 34, 35]. In the current study, we have co-cultured 
patient PBMC with HeLa cells stably expressing HLA-
DR1 or DR4, two alleles that were described to facilitate 
 IDH1R132H peptide-specific T cell responses [20], and loaded 
with  IDH1R132H peptide (Fig. 3a). Following 3–4 co-cultiva-
tion cycles, T cells were re-stimulated with peptide-loaded 
HeLa cells, yet again no consistent effect of mutated pep-
tide versus wild-type peptide towards T cell activation was 
observed in 6 out of 6 patient samples (Fig. 3b, c). Collec-
tively, when using PBMC from LGG patients who harbor 
the IDH1 mutant, whether or not pre-enriched for T cell 
reactivity against mutant IDH1 peptide, we did not observe 
 IDH1R132H-specific CD4 T cell responses.
No detection of  IDH1R132H‑specific T cells in tumor 
tissue
When compared to blood, the number of mutant-specific 
T cells may be enriched in  IDH1R132H expressing tumor 
tissue in case an effective T cell response had occurred 
[36–39], providing a rationale to screen for the presence of 
 IDH1R132H-specific CD4 T cells among TILs. TILs were 
polyclonally expanded from fresh resection material derived 
from 10 LGGs (with IDH1 mutation) and were subsequently 
stimulated with  IDH1R132H peptide loaded, irradiated autolo-
gous PBMCs. Also using TILs, we were not able to observe 
changes with respect to CD137 expression and IFN-γ pro-
duction of CD4 T cells for 10 out of 10 patients (Fig. 4).
Discussion
In this study, we focused on detecting the pres-
ence of  IDH1R132H-specific T and B cell reactivity in 
 IDH1R132H-mutant LGG patients. Detection of immune 
reactivity against this mutated peptide would warrant and at 
the same time facilitate the development of immunotherapy 
towards  IDH1R132H+ gliomas. Using various readouts for B 
Fig. 2  Blood of LGG patients do not harbor CD4 T cell reactivity 
against  IDH1R132H. PBMCs from patients with  IDH1R132H-positive 
gliomas were directly stimulated with  IDH1R132H or  IDH1WT pep-
tide for 16 h (n = 30 patients). a Percentage of CD137+ cells within 
CD4+ T cells. b IFN-γ response of the same T cell populations as in 
(a). Each dot represents an individual patient sample. MOG,  IDH1WT, 
and  IDH1R132H were corrected for the medium values. Medium, no 
peptide, negative control. SEB, staphylococcus-derived enterotoxin 
B, positive control. MOG, myelin oligodendrocyte glycoprotein pep-
tide, negative control
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and T cell responses, and using sera (n = 27 patients), PBMC 
(n = 30) as well as TILs (n = 10), we showed that immune 
cell populations with reactivity towards mutant IDH1 are not 
present in the LGG patient samples studied here.
These findings are in contrast to previous observations 
where Schumacher and colleagues demonstrated humoral 
and CD4 T cell responses in patients with glioma [20]. In 
our study we cannot exclude that we were not able to detect 
mutant-specific immune reactivity despite their presence in 
(a subset of) LGG patients and this could be due to a number 
of reasons.
First, levels of  IDH1R132H-specific antibodies or frequen-
cies of  IDH1R132H-specific CD4 T cells may be below the 
detection thresholds of assays. For instance, among TILs 
from (multiple and pooled)  IDH1R132H-mutant tumors, 
the frequency of  IDH1R132H-specific CD4 T cells was less 
than 2% (of CD4+ T cells) after vaccinating mice with 
mutant peptides [20]. Indeed, the central nervous system 
is considered to be immune-privileged, e.g. due to limited 
MHC expression, and consequently elicitation of robust 
glioma-specific immune responses may be limited [40]. 
Along this line, suppression of anti-tumor T cell immu-
nity by the oncometabolite d-2-hydroxyglutarate has also 
recently been described in LGG [41], which may further 
limit local activation of  IDH1R132H-specific CD4 T cells. 
A tentative low frequency of  IDH1R132H-specific CD4 T 
cells was addressed by pre-enrichment of these cells by 
co-culturing PBMC of  IDH1R132H-mutant patients with 
HeLa cells presenting  IDH1R132H. None of the samples 
showed a  IDH1R132H-specific T cell activation response, 
whether or not CD4 T cells underwent co-culture cycles 
with  IDH1R132H-presenting cells [42, 43]. Although the 
occurrence of very low frequencies of  IDH1R132H-specific 
T cells cannot be dismissed, and these could be targeted 
with enrichment protocols using more professional antigen-
presenting cells, optimal pMHC bindings [44] or in vivo 
Fig. 3  No CD4 T cell reactivity against  IDH1R132H despite long-
term pre-culture of CD4 T cells in presence of antigen. a Scheme 
of co-culture system used to enrich frequencies of mutant-specific T 
cells. In short, HLA-DR1 or DR4-positive patient PBMC were co-
cultured with HLA-DR1 or -DR4 transduced HeLa cells loaded with 
 IDH1R132H peptide or no peptide for 4 weeks. Prior to measurements 
of T cell activation, T cell populations (n = 6 patients) were stimu-
lated with DR1 or DR4-positive HeLa cells loaded with  IDH1R132H 
or  IDH1WT peptide for 16 h. b Percentage of CD137+ cells of CD4+ 
T cells. c IFN-γ response of the same T cell populations used in (b). 
Each dot represents an individual patient sample. DR1 + R132H, 
DR1 + WT, DR4 + R132H, DR4 + WT were corrected for the 
medium values. DR1, HeLa cells transduced with DRB1*01:01. 
DR4, HeLa cells transduced with DRB1*04:01
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vaccinations with  IDH1R132H [45], our data do suggest that 
the immunogenicity of  IDH1R132H is low.
Second, the number of patients assayed may have been 
too small in order to detect a cellular (n = 46; 36 PBMC and 
10 TIL samples) or humoral immune response (n = 27). Per-
centages of patients with antibody or CD4 T cell responses 
in blood have been reported to be as low as 10% and 16%, 
respectively [20]. However, even in the case of a popula-
tion frequency of 10%, there is a 94% chance of detecting 
at least one positive humoral response, and a 75% chance if 
the population frequency is 5% (using a cohort of 27 sam-
ples). Moreover, when combining the 36 PBMC and 10 TIL 
samples used to detect T-cell responses against  IDH1R132H, 
there is > 99% or 91% chance of detecting such responses 
in population frequencies of at least 10% or 5% respectively.
Third, we cannot exclude that  IDH1R132H may be pre-
sented by specific HLA alleles that are underrepresented 
in our cohort of tested patients and/or that expression lev-
els of IDH1 are too low to elicit  IDH1R132H-specific T-cell 
responses. Indeed, glioblastomas express IDH1 at higher 
levels compared to gliomas of lower grade (log2 expres-
sion levels of 10.9 ± 0.48 vs. 11.3 ± 0.49, vs. 11.4 ± 0.48 for 
grade II (n = 24), grade III (n = 85) and grade IV gliomas 
(n = 159) respectively [46]). However, the relative increase 
in IDH1 expression with increasing tumor grade is very 
modest and expression levels of IDH1 are in general rela-
tively high. Moreover, there is no difference between grade 
III astrocytomas and grade IV glioblastomas 11.4 ± 0.48 vs. 
11.4 ± 0.43, p = 0.89).
Taken together, our data does not provide evidence for 
detectable presence of immune cell reactivity towards 
 IDH1R132H in blood or tumors of LGG patients. We advocate 
further preclinical studies prior to development and clinical 
exploitation of T cell treatments directed against  IDH1R132H 
in LGG patients.
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